TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02508038

TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.

Status: 
Recruiting
Study Date: 
Fri, 01/01/2016 to Tue, 05/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT Patients will undergo a reduced-intensity conditioning regimen prior to transplant with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells using the CliniMACS System. Drug: Zoledronate Given IV. Patients (except those in Cohort A) will receive two doses of Zoledronate (at a 28 day interval) following transplant. Dose and post-transplant timing of Zoledronate administration is dependent upon patient Cohort. Other Names: Zoledronic Acid Zometa